Patents by Inventor SHERE BILLOUIN-FRAZIER

SHERE BILLOUIN-FRAZIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of detecting DDR2 mutations
    Patent number: 11118232
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: September 14, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • METHODS OF DETECTING DDR2 MUTATIONS
    Publication number: 20190177801
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 13, 2019
    Applicant: QUEST DIAGNOSTICS INVESTMENTS LLC
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • Methods of detecting DDR2 mutations
    Patent number: 10155994
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 18, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • DDR2 MUTATIONS AS TARGETABLE FEATURES OF MELANOMA OR BASAL CELL CARCINOMA
    Publication number: 20170260591
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 14, 2017
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • DDR2 mutations as targetable features of melanoma or basal cell carcinoma
    Patent number: 9617579
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: April 11, 2017
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • DDR2 MUTATIONS AS TARGETABLE FEATURES OF MELANOMA OR BASAL CELL CARCINOMA
    Publication number: 20140220032
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Application
    Filed: December 26, 2013
    Publication date: August 7, 2014
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: DANIEL M. JONES, YONGBAO WANG, SHERE BILLOUIN-FRAZIER, JUSTIN WINDHAM